Spero Therapeutics, Inc. (SPRO)
Largest Insider Buys in Sector
SPRO Stock Price History Chart
SPRO Stock Performance
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Spero Therapeutics, Inc.
Over the last 12 months, insiders at Spero Therapeutics, Inc. have bought $0 and sold $392,013 worth of Spero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Spero Therapeutics, Inc. have bought $22.14M and sold $3.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 39,727 shares for transaction amount of $207,971 was made by Aquilo Capital, L.P. () on 2022‑04‑26.
List of Insider Buy and Sell Transactions, Spero Therapeutics, Inc.
| 2024-02-05 | Sale | Shukla Sath | CEO and President | 45,093 0.0786% | $1.45 | $65,385 | +6.25% | |
| 2024-02-02 | Sale | Shukla Sath | CEO and President | 30,901 0.0509% | $1.37 | $42,334 | +4.79% | |
| 2024-02-02 | Sale | HAMED KAMAL | Chief Medical Officer | 28,075 0.0462% | $1.37 | $38,463 | +4.79% | |
| 2024-02-02 | Sale | Mahadevia Ankit | director | 63,795 0.105% | $1.37 | $87,399 | +4.79% | |
| 2024-02-02 | Sale | Keutzer Timothy | Chief Operating Officer | 30,971 0.0506% | $1.36 | $42,121 | +4.79% | |
| 2024-02-02 | Sale | JOSEPH TAMARA L | Chief Legal Officer | 30,906 0.0509% | $1.37 | $42,341 | +4.79% | |
| 2023-09-13 | Sale | HAMED KAMAL | Chief Medical Officer | 39,496 0.0732% | $1.27 | $50,160 | +10.85% | |
| 2023-08-29 | Sale | Shukla Sath | CEO and President | 4,163 0.0075% | $1.30 | $5,412 | +4.38% | |
| 2023-08-28 | Sale | Mahadevia Ankit | director | 9,040 0.0172% | $1.26 | $11,390 | +13.49% | |
| 2023-08-28 | Sale | Shukla Sath | CEO and President | 1,854 0.0035% | $1.26 | $2,336 | +13.49% | |
| 2023-08-28 | Sale | Keutzer Timothy | Chief Development Officer | 1,854 0.0035% | $1.26 | $2,336 | +13.49% | |
| 2023-08-28 | Sale | JOSEPH TAMARA L | Chief Legal Officer | 1,854 0.0035% | $1.26 | $2,336 | +13.49% | |
| 2023-02-03 | Sale | Mahadevia Ankit | CEO and President | 12,286 0.0223% | $1.81 | $22,238 | -23.68% | |
| 2023-02-02 | Sale | Keutzer Timothy | Chief Operating Officer | 3,394 0.0066% | $1.86 | $6,313 | -20.77% | |
| 2023-02-02 | Sale | JOSEPH TAMARA L | Chief Legal Officer | 3,394 0.0066% | $1.86 | $6,313 | -20.77% | |
| 2023-02-02 | Sale | Shukla Sath | Chief Financial Officer | 9,504 0.0181% | $1.83 | $17,372 | -20.77% | |
| 2022-08-29 | Sale | Shukla Sath | Chief Financial Officer | 6,017 0.017% | $0.89 | $5,378 | +96.02% | |
| 2022-04-26 | Aquilo Capital, L.P. | 39,727 0.1201% | $5.24 | $207,971 | -69.14% | |||
| 2022-03-30 | Aquilo Capital, L.P. | 33,115 0.1037% | $8.79 | $291,028 | -80.26% | |||
| 2022-03-14 | Aquilo Capital, L.P. | 8,006 0.0235% | $7.63 | $61,054 | -78.07% |
Insider Historical Profitability
| Shukla Sath | CEO and President | 1176007 2.2189% | $1.33 | 0 | 6 | |
| HAMED KAMAL | Chief Medical Officer | 788117 1.487% | $1.33 | 0 | 2 | |
| Mahadevia Ankit | director | 744997 1.4057% | $1.33 | 0 | 18 | |
| Keutzer Timothy | Chief Operating Officer | 534050 1.0077% | $1.33 | 0 | 3 | |
| JOSEPH TAMARA L | Chief Legal Officer | 531615 1.0031% | $1.33 | 0 | 3 | |
| Aquilo Capital, L.P. | 5321231 10.0402% | $1.33 | 3 | 0 | ||
| Aquilo Capital Management, LLC | 10 percent owner | 5207796 9.8262% | $1.33 | 21 | 11 | |
| FORMELA JEAN FRANCOIS | director | 2408128 4.5437% | $1.33 | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1934006 3.6491% | $1.33 | 2 | 0 | <0.0001% |
| Goyal Vikas | director | 1854006 3.4982% | $1.33 | 1 | 0 | <0.0001% |
| Breum Casper | director | 1091774 2.06% | $1.33 | 1 | 0 | <0.0001% |
| Sendek Joel | Chief Financial Officer | 15181 0.0286% | $1.33 | 1 | 1 | <0.0001% |
| Larkin Cristina | Chief Operating Officer | 1500 0.0028% | $1.33 | 1 | 2 | <0.0001% |
Institutional Investor Ownership
| Anson Funds Management Lp | $6.45M | 6.95 | 3.75M | -12.73% | -$941,268.28 | 0.3 | |
| The Vanguard Group | $2.84M | 3.06 | 1.65M | +0.59% | +$16,641.00 | <0.0001 | |
| Alphabet | $1.53M | 1.65 | 889,979 | 0% | +$0 | 0.06 | |
| Murchinson Ltd | $1.5M | 1.62 | 873,910 | +1.3% | +$19,281.20 | 0.17 | |
| Renaissance Technologies | $1.47M | 1.58 | 854,460 | +56.08% | +$528,149.53 | <0.01 | |
| Acadian Asset Management | $1.31M | 1.41 | 762,598 | +121.78% | +$719,320.04 | 0.01 | |
| Atlas Venture Life Science Advisors Llc | $1.05M | 1.13 | 607,613 | -40.04% | -$698,018.76 | 0.1 | |
| BlackRock | $820,261.00 | 0.88 | 476,896 | -0.77% | -$6,369.16 | <0.0001 | |
| Geode Capital Management | $807,631.00 | 0.87 | 469,441 | +13.75% | +$97,605.74 | <0.0001 | |
| Novo Holdings A/S | $806,511.00 | 0.87 | 468,902 | 0% | +$0 | 0.06 | |
| Awm Investment Company Inc | $573,448.00 | 0.62 | 333,400 | 0% | +$0 | 0.09 | |
| Shay Capital Llc | $527,983.00 | 0.57 | 306,967 | New | +$527,983.00 | 0.16 | |
| Man Group Plc | $368,125.00 | 0.4 | 214,026 | New | +$368,125.00 | <0.01 | |
| Bridgeway Capital Management | $317,856.00 | 0.34 | 184,800 | +37.09% | +$86,000.00 | 0.01 | |
| Millennium Management LLC | $254,340.00 | 0.27 | 147,872 | -0.66% | -$1,694.20 | <0.0001 | |
| State Street | $224,479.00 | 0.24 | 130,511 | 0% | +$0 | <0.0001 | |
| DAFNA Capital Management, LLC | $215,000.00 | 0.23 | 125,000 | 0% | +$0 | 0.05 | |
| Northern Trust | $197,042.00 | 0.21 | 114,559 | +28.89% | +$44,166.28 | <0.0001 | |
| Squarepoint Ops LLC | $136,570.00 | 0.15 | 79,401 | -35.34% | -$74,649.87 | <0.01 | |
| Bank of Montreal | $139,920.00 | 0.15 | 79,500 | New | +$139,920.00 | <0.0001 | |
| Bailard Inc | $104,748.00 | 0.11 | 60,900 | New | +$104,748.00 | <0.01 | |
| Charles Schwab | $49,132.00 | 0.05 | 28,565 | 0% | +$0 | <0.0001 | |
| Mackenzie Financial Corp | $48,920.00 | 0.05 | 28,442 | +32.52% | +$12,005.54 | <0.0001 | |
| Gsa Capital Partners Llp | $49,000.00 | 0.05 | 28,319 | New | +$49,000.00 | <0.01 | |
| Prudential Financial | $43,688.00 | 0.05 | 25,400 | -9.93% | -$4,816.00 | <0.0001 | |
| Virtu Financial Llc | $31,000.00 | 0.03 | 18,180 | New | +$31,000.00 | <0.01 | |
| Xtx Topco Ltd | $25,822.00 | 0.03 | 15,013 | -77.24% | -$87,637.94 | <0.01 | |
| Dimensional Fund Advisors | $17,205.00 | 0.02 | 10,003 | 0% | +$0 | <0.0001 | |
| Texas Yale Capital Corp | $17,200.00 | 0.02 | 10,000 | 0% | +$0 | <0.01 | |
| Morgan Stanley | $13,586.00 | 0.02 | 7,899 | -34.37% | -$7,113.77 | <0.0001 | |
| Russell Investments Group Ltd | $11,008.00 | 0.01 | 6,400 | 0% | +$0 | <0.0001 | |
| UBS | $9,852.00 | 0.01 | 5,728 | +1,641.03% | +$9,286.13 | <0.0001 | |
| Bank of America | $8,930.00 | 0.01 | 5,192 | -9.7% | -$959.73 | <0.0001 | |
| Fidelity Investments | $4,109.00 | <0.01 | 2,389 | +1,164.02% | +$3,783.93 | <0.0001 | |
| LAZARD ASSET MANAGEMENT LLC | $2,000.00 | <0.01 | 1,248 | New | +$2,000.00 | <0.0001 | |
| Wells Fargo | $929.00 | <0.01 | 540 | +1.31% | +$12.04 | <0.0001 | |
| RhumbLine Advisers | $787.00 | <0.01 | 458 | 0% | +$0 | <0.0001 | |
| Allworth Financial Lp | $1,032.00 | <0.01 | 600 | 0% | +$0 | <0.0001 | |
| Raleigh Capital Management Inc | $860.00 | <0.01 | 500 | New | +$860.00 | <0.0001 | |
| U.S. Bancorp | $260.00 | <0.01 | 151 | 0% | +$0 | <0.0001 | |
| Newedge Advisors Llc | $172.00 | <0.01 | 100 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $406.00 | <0.01 | 236 | 0% | +$0 | <0.0001 | |
| Advisor Group Holdings Inc | $81.00 | <0.01 | 47 | -51.55% | -$86.17 | <0.0001 | |
| Tower Research Capital | $372.00 | <0.01 | 216 | +21,500% | +$370.28 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 |